March 13, 2009 -Medical device pioneer Stentys said today it extended its self-expanding and disconnectable technology platform to include a second major indication - acute myocardial infarction (AMI).
Two patients were successfully treated during AMI procedures last week by Drs. S. Verheye in Antwerp, Belgium and K. E. Hauptmann in Trier, Germany.
The versatile Stentys platform features self-expansion and disconnectability. The company said the self-expanding feature insures optimal apposition in the critical initial hours and days after the procedure by being constantly applied to the vessel surface during thrombus and vessel spasm relief, therefore avoiding malapposition. The disconnectability feature is designed to treat lesions close to a bifurcation, by ensuring safe main branch provisional stenting and optimal side branch access when needed. Equally important, the Stentys platform is implanted by usual stenting techniques requiring no additional training, the company said.
“The Stentys device was simple to implant, conformed snugly to the treated vessel, and created minimal vessel injury since no high-pressure inflation was required,” said Dr. Verheye. “When comparing immediate and five days post-procedure results using IVUS, the coronary vessel expanded slightly and Stentys followed intimately the vessel remodeling with perfect apposition.”
Based in Paris, France, and Princeton, N.J., Stentys, a privately held company, has developed a self-expanding platform aimed at enhancing the treatment of complex coronary lesions such as acute coronary syndromes or lesions close to coronary bifurcations. The company’s products are not currently FDA approved.
For more information: www.stentys.com
October 16, 2024 
